PE-22-28

Description

PE-22-28

Also known as: PE22-28, Spadin Analog, TREK-1 Inhibitor Peptide

PE-22-28 is an experimental neuroactive peptide originating from the spadin/TREK-1 signaling pathway, currently under investigation for its possible role in regulating mood, supporting neuroprotection, enhancing cognition, improving resilience to stress, and promoting neurogenesis. Its primary mechanism involves inhibiting the TREK-1 potassium channel, a function linked in preclinical studies to antidepressant-like outcomes and increased neural plasticity. Due to its fast-acting profile in mood and cognitive research, PE-22-28 has attracted considerable attention within cutting-edge nootropic and peptide research circles.

• Status: Preclinical phase – research conducted exclusively in animal models. Evidence classification: Based on animal studies.
• Common dosage range: 100 to 300 mcg administered once daily via intranasal or subcutaneous routes.
• Investigated applications: Depression, anxiety, mood regulation, and general mental well-being.